Janus 激酶抑制剂：处方授权与报销之间的关系。

IF 1.2 Q4 RHEUMATOLOGY

Reumatismo Pub Date : 2023-12-19 DOI:10.4081/reumatismo.2023.1627

F R Spinelli, F Conti, R Caporali, F Iannone, F Cacciapaglia, On Behalf Of The Steering Committee Of The Italian Society Of Rheumatology

引用次数: 0

摘要

在意大利药品管理局对 Janus 激酶抑制剂的可报销性进行限制之后，意大利风湿病学会起草了本文件，以阐明处方中规定的临床条件和可报销性标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Janus kinase inhibitors: between prescription authorization and reimbursability.

Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Reumatismo RHEUMATOLOGY-

CiteScore

2.10

自引率

7.10%

发文量

审稿时长

10 weeks

期刊介绍： Reumatismo is the official Journal of the Italian Society of Rheumatology (SIR). It publishes Abstracts and Proceedings of Italian Congresses and original papers concerning rheumatology. Reumatismo is published quarterly and is sent free of charge to the Members of the SIR who regularly pay the annual fee. Those who are not Members of the SIR as well as Corporations and Institutions may also subscribe to the Journal.